Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Antithymocyte globulin (ATG), Antithymocyte globulin, Anti-Thymocyte globulin (rabbit)
Anti-Thymocyte globulin · 2 trials · 4 indications
Registration will be documented by the Clinical Research Organization (Ozmosis Research Inc.)
| Arm | Type | Description |
|---|---|---|
| ATG/PTCy | EXPERIMENTAL | Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1); cyclophosphamide (Post Transplant Cyclophosphamide, PTCy) 50 mg/kg IV daily on days +3 and +4. |
| ATG | ACTIVE_COMPARATOR | Anti-Thymocyte Globulin (ATG, Thymoglobulin) 4.5 mg/kg IV (divided 0.5, 2.0, 2.0 mg/kg on days -2, -1 and +1). |
| Name | Type | Description |
|---|---|---|
| Cyclophosphamide | DRUG | Post Transplant Cyclophosphamide |
| Anti-Thymocyte globulin (rabbit) | DRUG | Anti-Thymocyte Globulin (rabbit, Thymoglobulin) |
| anti-thymocyte globulin | BIOLOGICAL | - |
Inclusion Criteria: 1. The participant is aged ≥ 16 and deemed medically fit per investigator for protocol 2. The participant has either acute myeloid leukemia in 1st or 2nd complete remission (CR), or has myelodysplastic syndrome 3. The participant will receive a blood progenitor cell graft ("HPC,...
Anti-Thymocyte globulin (ATG) is used in the treatment of Myelodysplastic Syndromes and Acute Leukemia. It is being studied in clinical trials for these conditions, including a completed Phase 2 trial in Myelodysplastic Syndromes and an active Phase 2 trial in Acute Leukemia and Myelodysplasia.
Anti-Thymocyte globulin targets T lymphocytes, which are a type of white blood cell involved in the immune response. By depleting these cells, it modulates the immune system, which is relevant in the treatment of hematologic conditions like Myelodysplastic Syndromes and Acute Leukemia.
Anti-Thymocyte globulin is developed by Sanofi, a global biopharmaceutical company. Sanofi is listed on the stock exchange under the ticker symbol SNY.
Anti-Thymocyte globulin is in Phase 2 clinical development. It has completed a Phase 2 trial in Myelodysplastic Syndromes and is currently in an active Phase 2 trial for Acute Leukemia and Myelodysplasia. It is an investigational drug and has not been approved by regulatory authorities.
Anti-Thymocyte globulin is involved in two clinical trials. The first, NCT00017550, is a completed Phase 2 trial comparing ATG with supportive care in patients with Myelodysplastic Syndrome. The second, NCT04202835, is an active Phase 2 trial studying ATG plus PTCy versus ATG for chronic graft-versus-host disease prophylaxis in Acute Leukemia and Myelodysplasia.
Yes, Anti-Thymocyte globulin is also known as Antithymocyte globulin (ATG) and Anti-Thymocyte globulin (rabbit). These names refer to the same drug, which is developed by Sanofi and is being studied for Myelodysplastic Syndromes and Acute Leukemia.